Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs Duolingo Inc (DUOL) Price & Performance

Amgen, Inc.
Duolingo Inc

Price performance

Price movement over the last 24 hours

Key statistics

Amgen, Inc. vs Duolingo Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Duolingo Inc trades at $125.99 (market cap $5.81B). The key difference: Amgen, Inc. is far larger — about 33.8× Duolingo Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Duolingo Inc pays none. Which is the better fit depends on your goals.

AMGNDUOL
Market Cap
$196.12B$5.81B
Sector
HealthTechnology
52-Week High
$388.16$390.84
52-Week Low
$271.18$90.03
Enterprise Value
$241.41B$4.65B
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.

The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.

Duolingo Inc

Duolingo stock trades at $124.76, down 3.99% on the day, as the language learning platform shows strong fundamental performance with revenue reaching $1.04 billion in 2025 and net income of $414 million. The company has consistently beaten earnings expectations in recent quarters, with technical indicators showing a bullish trend despite some overbought signals. Recent news highlights AI integration improvements and user growth potential, with the stock trading above analyst consensus price targets.

Duolingo presents a compelling growth story with robust profitability metrics and expanding user base, though valuation remains elevated. Key risks include AI disruption concerns and competitive pressures in the edtech space. The current price offers potential upside to high analyst targets but requires monitoring of user growth sustainability and margin trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

Read more on DUOL